Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference Summary Webcast / Call
July 07 2015 - 7:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) and its
subsidiary, Macrophage Therapeutics, Inc., will hold a
post-International Workshop on Kaposi's Sarcoma Herpesvirus
(KSHV) and Related Agents conference webcast to provide
investors with a more detailed look at the recently presented
Manocept™ platform clinical and pre-clinical data and results
disclosed in today’s press releases. The webcast will take place on
July 7, 2015 at 1:00 pm EDT. Rick Gonzalez, Navidea’s CEO and
Michael Goldberg, M.D., Macrophage Therapeutics’ CEO will host the
call along with Michael S. McGrath, M.D., Ph.D., Professor,
Departments of Laboratory Medicine, Pathology, and Medicine at the
University of California, San Francisco who will discuss the data
presented.
CONFERENCE CALL DETAILS
Investors and the public are invited to access the live audio
webcast through the link below. Participants who would like to ask
questions during the question and answer session must participate
by telephone also. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The
webcast replay is expected to be available on our investor website,
http://ir.navidea.com, two to four hours after the live event.
Event: Macrophage Therapeutics KSHV Results
Conference Call Date/Time: Tuesday, July 7, 2015 at 1:00 p.m. EDT
Webcast Link:
http://public.viavid.com/index.php?id=115204
Live Dial-in Number – US: 1 (877) 407-0789 Live Dial in Number –
Int’l:
1 (201) 689-8562
Replay Dial-in Number –US:
1 (877) 870-5176
Replay Dial-in Number –Int’l.:
1 (858) 384-5517 Replay PIN Number: 13613882
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
About Macrophage Therapeutics
Macrophage Therapeutics, Inc., a newly created subsidiary of
Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics
using the patented Manocept immunotherapy platform licensed from
Navidea to target over-active macrophages implicated in cancer,
cardiovascular, central nervous system, autoimmune, antiviral, and
skin diseases. Manocept specifically targets CD206, or the mannose
receptor prevalent on over-active macrophages. The technology
enables highly specific targeted delivery of active (either
existing or yet to be developed) agents that can modulate the
activity of over-active macrophages that have been implicated in
many diseases. Targeted delivery should significantly enhance a
given compound’s efficacy and safety.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150707005742/en/
Macrophage TherapeuticsJames Goldschmidt, Ph.D.,
484-225-0341jgoldschmidt@macrophagetx.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024